Latest News

2 EV Stocks That Are Set to Keep Growing; Analyst Says ‘Buy’

0

InvestorPlace

Cassava Stock Could Jump More Than 200 Times

Given the potential, tremendous benefits of Cassava’s Alzheimer’s drug for millions of patients and the high probability of the drug being approved, I believe that Cassava Sciences (NASDAQ:SAVA) stock is vastly undervalued. Source: Pavel Kapysh / Shutterstock.com Additionally, my calculations indicate that the shares could easily soar over 200x after the company’s Alzheimer’s treatment, simufilam, is approved by the FDA. Meanwhile, there’s evidence that strong support for the drug is building am

‘I promised myself I’d never be that broke again.’ This financial adviser’s family inherited $1.4 million and quickly lost it all.

Previous article

Plug Power Stock Forecast: Where the Pros Think PLUG Could Go

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News